Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affair and Brand Strategy Officer David Chang - President and Chief Executive Officer Zachary Roberts - EVP of Research and Development and Chief Medical Officer Geoff Parker - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Jack Allen - Baird Biren Amin - Piper Sandler John Newman - Canaccord Genuity Luca Issi - RBC Capital Samantha Semenkow - Citi Matthew Biegler - Oppenheimer Brooke Schuster - William Blair William Pickering - Bernstein Laura Prendergast - Raymond James Operator Hello, and thank you for standing by. Welcome to Allogene Therapeutics' Third Quarter 2024 Conference Call.
Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know
Allogene Therapeutics (ALLO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity
Allogene Therapeutics, Inc. (ALLO, Financial) saw a significant drop in its stock price, falling 5.06% to $2.54 per share. The trading volume reached 1.41 million shares, with a turnover rate of 0.67% and a volatility of 4.49%.
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
Positive interim results released from phase 1/1b study using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory Multiple Myeloma. The global multiple myeloma market is projected to reach $44.22 billion by 2032. Interim data update for use of P-CD19CD20-ALLO1 in ongoing phase 1 study targeting patients with B-cell malignancies expected in the 2nd half of 2024 pending coordination with Roche.
3 Hot Penny Stocks to Buy With $1000
Penny stocks are some of my favorite stocks to watch.
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Christine Cassiano - Executive Vice President, Chief Corporate Officer and IR David Chang - President, Chief Executive Officer and Co-Founder Zachary Roberts - Executive Vice President of Research & Development and Chief Medical Officer Geoffrey Parker - Executive Vice President and Chief Financial Officer Conference Call Participants Brian Chinn - JPMorgan Jenna Li - Jefferies Tyler Van Buren - TD Cowen Jack Allen - Baird Asthika Goonewardene - Truist Brooke Schuster - William Blair Matthew Biegler - Oppenheimer John Newman - Canaccord Benjamin Burnett - Stifel Luca Issi - RBC Capital Tashdid Hasan - Rodman & Renshaw Reni Benjamin - Citizens JMP Biren Amin - Piper Sandler William Pickering - Bernstein Operator Hello, and thank you for standing by. Welcome to Allogene Therapeutics' Second Quarter 2024 Conference Call.
Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.
7 Biotech Stocks to Buy for Their Game-Changing Potential
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.
If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names
Penny stocks carry a great deal of risk. It's why investors are often told to steer clear of them.
